Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| French Sarcoma Group | OTHER |
Not provided
Not provided
Not provided
Not provided
The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas [RESOS] / French expert network dedicated to the pathology of sarcomas [RREPS]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas [NETSARC]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.
Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes.
With the financial support of the French National Cancer Institute [Institut National du cancer [INCa]).](streamdown:incomplete-link)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with sarcoma | Patients with a sarcoma diagnosed in a French Comprehensive cancer Center |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Chemotherapy | Drug | treatment as per standard of care |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Time to next treatment (TNT) | Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact. | 2 years |
| Time to next treatment (TNT) | Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact. | 5 years |
| Overall survival (OS) | Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact. | 2 years |
| Overall survival (OS) | Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact. | 5 years |
Not provided
Not provided
Inclusion criteria :
Not provided
Not provided
Not provided
Not provided
Diagnosis of sarcoma
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Maud Toulmonde, MD | Contact | 0556333333 | m.toulmonde@bordeaux.unicancer.fr | |
| Simone Mathoulin-Pélissier, MD/PhD | Contact | 05563333 | s.mathoulin@bordeaux.unicancer.fr |
| Name | Affiliation | Role |
|---|---|---|
| Maud Toulmonde, MD | Institut Bergonié, Bordeaux, France | Study Chair |
| Axel Le Cesne, MD/PhD | Institut Gustave Roussy, Villejuif, France | Study Chair |
| Jean-Yves Blay, MD/PhD |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Bergonié, Comprehensive Cancer Center | Recruiting | Bordeaux | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28391775 | Result | Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, Cousin S, Terrier P, Ranchere-Vince D, Meeus P, Stoeckle E, Honore C, Sargos P, Sunyach MP, Le Pechoux C, Giraud A, Bellera C, Le Loarer F, Italiano A. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017 Apr 10;15(1):78. doi: 10.1186/s12916-017-0831-7. | |
| 24567518 |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012509 | Sarcoma |
| ID | Term |
|---|---|
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| D000276 | Adjuvants, Immunologic |
| D013514 | Surgical Procedures, Operative |
| D011878 | Radiotherapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
| D007155 | Immunologic Factors |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
| Immunotherapeutic Agent |
| Drug |
treatment as per standard of care |
|
| target treatment | Drug | treatment as per standard of care |
|
| Surgery | Procedure | treatment as per standard of care |
|
| Radiotherapy | Radiation | treatment as per standard of care |
|
| Centre Léon Bérard, Lyon, France |
| Study Chair |
| Centre Léon Bérard | Recruiting | Lyon | France |
|
| Institut Gustave Roussy, Comprehensive Cancer Center | Recruiting | Villejuif | France |
|
| Result |
| Toulmonde M, Bonvalot S, Meeus P, Stoeckle E, Riou O, Isambert N, Bompas E, Jafari M, Delcambre-Lair C, Saada E, Le Cesne A, Le Pechoux C, Blay JY, Piperno-Neumann S, Chevreau C, Bay JO, Brouste V, Terrier P, Ranchere-Vince D, Neuville A, Italiano A; French Sarcoma Group. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014 Mar;25(3):735-742. doi: 10.1093/annonc/mdt577. |
| 29117335 | Result | Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, Mir O, Adam J, Chevreau C, Bonvalot S, Rios M, Kerbrat P, Cupissol D, Anract P, Gouin F, Kurtz JE, Lebbe C, Isambert N, Bertucci F, Toumonde M, Thyss A, Piperno-Neumann S, Dubray-Longeras P, Meeus P, Ducimetiere F, Giraud A, Coindre JM, Ray-Coquard I, Italiano A, Le Cesne A. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017 Nov 1;28(11):2852-2859. doi: 10.1093/annonc/mdx484. |
| D020164 |
| Chemical Actions and Uses |